Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.
Revenue of Assertio Holdings, Inc. (ASRT)
Revenue in 2023 (TTM): $152.07 M
According to Assertio Holdings, Inc.'s latest financial reports the company's current revenue (TTM) is $152.07 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Assertio Holdings, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $152.07 M | $125.05 M | $-222,447,000 | $-254,054,000 | $-331,942,000 |
| 2022 | $156.23 M | $137.49 M | $72.54 M | $31.17 M | $109.63 M |
| 2021 | $111.01 M | $95.18 M | $38.78 M | $-553,000 | $-1,281,000 |
| 2020 | $106.28 M | $86.4 M | $-3,204,000 | $-45,513,000 | $-28,144,000 |
| 2019 | $229.5 M | $220 M | $-61,121,000 | $-222,484,000 | $-217,201,000 |
| 2018 | $311.77 M | $293.29 M | $213.16 M | $37.98 M | $36.91 M |
| 2017 | $380.72 M | $308.13 M | $74.05 M | $-103,924,000 | $-102,496,000 |
| 2016 | $455.9 M | $368.48 M | $133.76 M | $-64,502,000 | $-88,720,000 |
| 2015 | $342.74 M | $274.84 M | $35.94 M | $-123,237,000 | $-75,738,000 |
| 2014 | $390.36 M | $375.22 M | $252.64 M | $213.11 M | $131.76 M |
| 2013 | $134.21 M | $127.11 M | $16.68 M | $4.58 M | $43.31 M |
| 2012 | $90.82 M | $84.78 M | $-27,272,000 | $-29,872,000 | $-29,781,000 |
| 2011 | $132.97 M | $127.43 M | $71.68 M | $71.12 M | $70.73 M |
| 2010 | $80.76 M | $72.67 M | $4.9 M | $3.89 M | $3.9 M |
| 2009 | $57.73 M | $52.47 M | $-20,214,000 | $-22,023,000 | $-22,008,000 |
| 2008 | $34.84 M | $29.07 M | $-13,598,000 | $-15,301,000 | $-15,302,000 |
| 2007 | $65.58 M | $62.99 M | $48.4 M | $49.81 M | $49.22 M |
| 2006 | $9.55 M | $7.95 M | $-40,227,000 | $-39,576,788 | $-39,659,288 |
| 2005 | $4.41 M | $3.5 M | $-25,372,615 | $-24,467,272 | $-24,467,272 |
| 2004 | $202.57 K | $202.57 K | $-24,633,502 | $-26,774,637 | $-26,873,637 |
| 2003 | $981.99 K | $981.99 K | $-28,353,777 | $-29,403,814 | $-30,015,098 |
| 2002 | $1.66 M | $1.66 M | $-27,682,294 | $-12,863,105 | $-13,494,565 |
| 2001 | $3.67 M | $3.67 M | $-13,710,616 | $-17,494,836 | $-17,600,039 |
| 2000 | $1.78 M | $2.34 M | $-7,176,434 | $-9,925,824 | $-9,702,870 |
| 1999 | $115.33 K | $758.82 K | $-4,846,974 | $-17,505,465 | $-17,208,800 |
| 1998 | $800 K | $1.3 M | $-2,836,862 | $-2,800,000 | $-2,800,000 |
| 1997 | $600 K | $800 K | $-1,000,000 | $ | $-1,200,000 |
| 1996 | $300 K | $300 K | $-500,000 | $ | $-500,000 |